Bioavailability and Anticonvulsant Activity of a Monoglyceride-derived Prodrug of Phenytoin After Oral-administration To Rats
Scriba, GKE.;Lambert, DM.;Poupaert, Jacques
(1995) Journal of Pharmaceutical Sciences — Vol. 84, n° 3, p. 300-302 (1995)
Files
No attached file found for this publication.
Details
Authors
Scriba, GKE.
Author
Lambert, DM.
Author
Poupaert, JacquesUCLouvain
Author
Abstract
The plasma levels of phenytoin after oral administration of phenytoin and phenytoin 2-monoglyceride, a phenytoin prodrug, to rats were determined by gas chromatography. Compared to the application of the parent drug, administration of the prodrug resulted in a 3-fold increase of C-max and a 4-fold increase of the AUC. This correlated with an earlier onset and peaking of the anticonvulsant activity determined in the maximal electroshock (MES) test. The peak effect was reached 1 h after dosing the monoglyceride compared to 2 h after application of phenytoin itself. On the basis of the median effective dose, the prodrug was 3 times more effective antagonizing MES-induced seizures than the parent drug. It is concluded that phenytoin 2-monoglyceride might be a useful prodrug for the oral delivery of phenytoin.
Scriba, GKE., Lambert, DM., & Poupaert, J. (1995). Bioavailability and Anticonvulsant Activity of a Monoglyceride-derived Prodrug of Phenytoin After Oral-administration To Rats. Journal of Pharmaceutical Sciences, 84(3), 300-302. https://doi.org/10.1002/jps.2600840307 (Original work published 1995)